Cybin announces more early success with with its Kernel Flow(R) technology to measure the neurological effects of ketamine therapy.

Pharmather announces receiving a patent from the USPTO for its “ketamine flow synthesis”. Pharmather has exclusive worldwide development and commercial rights to this IP.

Wesana announces a strategic review of its assets and a decision to focus on drug development.

Optimi Health announces receiving amendment to Health Canada’s Dealer’s License that will allow expand cultivation and research use of psilocybin and psilocin.

Wesana reports its Q4 2021 financial results and announces closing of a financing.

Mydecine announces raising $1,693,434.60 in addition to gross proceeds of $333,333.35 announced on March 22, 2022.

Delic Holdings announces a new health & wellness therapy offered through its Ketamine Wellness Centers mental health clinics.

Awakn Life Sciences reports fourth quarter and full-year results for its fiscal year ending January 31, 2022. Annual revenues of CAD$236,037.

Tryp Therapeutics announces initial patient enrollment in its Phase II clinical trial of a psilocybin-based compound (TRP-8802) for Binge Eating Disorder.

Field Trip announces its corporate decision to separate Field Trip Health and Field Trip Discovery into separate companies.